BR112022010488A2 - Formulação farmacêutica, uso da formulação farmacêutica, e, método para tratamento de um paciente - Google Patents

Formulação farmacêutica, uso da formulação farmacêutica, e, método para tratamento de um paciente

Info

Publication number
BR112022010488A2
BR112022010488A2 BR112022010488A BR112022010488A BR112022010488A2 BR 112022010488 A2 BR112022010488 A2 BR 112022010488A2 BR 112022010488 A BR112022010488 A BR 112022010488A BR 112022010488 A BR112022010488 A BR 112022010488A BR 112022010488 A2 BR112022010488 A2 BR 112022010488A2
Authority
BR
Brazil
Prior art keywords
pharmaceutical formulation
patient
treatment
formulations
pharmaceutical
Prior art date
Application number
BR112022010488A
Other languages
English (en)
Inventor
Saddan Hernández Terrero Yaiko
Lidea Fernández Sáez Olga
Felipe Santo Tomás Pompa Julio
Cedeño Arias Mercedes
Rashida De La Luz Hernández Kathya
Boggiano Ayo Tammy
León Monzón Kalet
Castillo Vitloch Adolfo
Original Assignee
Ct Inmunologia Molecular
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct Inmunologia Molecular filed Critical Ct Inmunologia Molecular
Publication of BR112022010488A2 publication Critical patent/BR112022010488A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

FORMULAÇÃO FARMACÊUTICA, USO DA FORMULAÇÃO FARMACÊUTICA, E, MÉTODO PARA TRATAMENTO DE UM PACIENT. A presente invenção refere-se aos ramos de biotecnologia e medicina e descreve formulações farmacêuticas altamente concentradas compreendendo o anticorpo monoclonal humanizado nimotuzumabe em uma faixa de concentração dentro de 50 a 200 mg/mL. A baixa viscosidade dessas soluções permite que elas sejam usadas por via subcutânea ou intramuscular nos tratamentos do câncer. Estas formulações são estáveis tanto em suas formas líquidas quanto liofilizadas.
BR112022010488A 2019-12-17 2020-12-10 Formulação farmacêutica, uso da formulação farmacêutica, e, método para tratamento de um paciente BR112022010488A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CU2019000104A CU20190104A7 (es) 2019-12-17 2019-12-17 Formulación estable del anticuerpo nimotuzumab
PCT/CU2020/050007 WO2021121444A2 (es) 2019-12-17 2020-12-10 Formulación estable y de alta concentración del anticuerpo nimotuzumab

Publications (1)

Publication Number Publication Date
BR112022010488A2 true BR112022010488A2 (pt) 2022-09-06

Family

ID=76478863

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022010488A BR112022010488A2 (pt) 2019-12-17 2020-12-10 Formulação farmacêutica, uso da formulação farmacêutica, e, método para tratamento de um paciente

Country Status (12)

Country Link
US (1) US20230018364A1 (pt)
EP (1) EP4079294A2 (pt)
JP (1) JP2023509354A (pt)
KR (1) KR20220119091A (pt)
CN (1) CN114867468A (pt)
AU (1) AU2020409887B2 (pt)
BR (1) BR112022010488A2 (pt)
CA (1) CA3163630A1 (pt)
CO (1) CO2022009693A2 (pt)
CU (1) CU20190104A7 (pt)
MX (1) MX2022007509A (pt)
WO (1) WO2021121444A2 (pt)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100158925A1 (en) * 2006-06-14 2010-06-24 Meera Agarkhed Lyophilized formulations of anti-egfr antibodies
US9345661B2 (en) 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
AR078161A1 (es) 2009-09-11 2011-10-19 Hoffmann La Roche Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
JP2013515754A (ja) 2009-12-29 2013-05-09 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 新規な抗体製剤
US20190374639A1 (en) * 2016-11-21 2019-12-12 Polpharma Biologics S.A. Aqueous pharmaceutical formulations
CN107898756B (zh) 2017-12-22 2020-11-20 东曜药业有限公司 一种用于皮下或肌肉注射的高浓度尼妥珠单抗制剂及其制备方法和应用

Also Published As

Publication number Publication date
KR20220119091A (ko) 2022-08-26
CN114867468A (zh) 2022-08-05
WO2021121444A2 (es) 2021-06-24
AU2020409887A1 (en) 2022-08-11
CU20190104A7 (es) 2021-08-06
US20230018364A1 (en) 2023-01-19
CA3163630A1 (en) 2021-06-24
MX2022007509A (es) 2022-07-01
CO2022009693A2 (es) 2022-07-19
JP2023509354A (ja) 2023-03-08
AU2020409887B2 (en) 2024-08-08
WO2021121444A3 (es) 2022-02-24
EP4079294A2 (en) 2022-10-26

Similar Documents

Publication Publication Date Title
CY1123657T1 (el) Σταθερη φαρμακοτεχνικη μορφη anti-ifnar1
EA201792273A1 (ru) Композиции, содержащие комбинацию анти-pd-1 антитела и другого антитела
BR112019022972A2 (pt) Fomulações estáveis de anticorpos de receptor de morte programada 1 (pd-1) e métodos de uso das mesmas
BRPI0516299B8 (pt) formulação farmacêutica e uso de uma formulação farmacêutica
MA47313B1 (fr) Formulations sous-cutanées d'anticorps her2
BR112012022223A8 (pt) Formulação de proteína concentrada, uso e método de preparação da mesma
BR112014028633A8 (pt) tratamento de amd usando sflt-1 de aav
BR112014028600A8 (pt) Formulações de suspensão compreendendo anticorpo monoclonal de alta concentração, seu método de preparação, seu uso e dispositivo para sua administração subcutânea, e método para produção de um artigo de fabricação
AR111497A1 (es) Formulaciones de anticuerpos humanos anti-rankl y métodos de uso de estos
BR112016008010A2 (pt) uso de moléculas de ligação de semaforina-4d para tratamento de aterosclerose
BR112019022280A2 (pt) tratamento de cânceres de her2 positivo
EA202091318A1 (ru) Препарат, содержащий аденовирус группы b
BR112018076639A2 (pt) quimioterapias de combinação
BR112021015036A2 (pt) Tratamento para câncer com imunoconjugados do anticorpo ror1
BR112022012437A2 (pt) Método de tratamento de um câncer compreendendo a administração de uma molécula biespecífica pd-1 x lag-3 a um indivíduo em necessidade deste e método de tratamento de um câncer em um indivíduo
EA202193240A1 (ru) Стабилизированные составы, содержащие анти-angptl3 антитела
AR091155A1 (es) Composicion farmaceutica acuosa que contiene un agente terapeutico biologico y guanidina o un derivado de guanidina y una inyeccion que incluye la composicion
BR112022001492A2 (pt) Anticorpo anti-il17a humanizado e uso do mesmo
BR112021025394A2 (pt) Derivados de antraciclina, conjugados de fármaco e molécula de ligação ao alvo, uso de conjugado de fármaco e molécula de ligação ao alvo, método de tratamento de uma doença em um paciente em necessidade de tratamento, e composição farmacêutica
BR112021014854A2 (pt) Tratamento de lesões de pele e prurido em pacientes com prurigo nodularisis
BR112014016723A2 (pt) método para o tratamento de câncer de mama
BR112020004935A2 (pt) Composição farmacêutica compreendendo um anticorpo que se liga especificamente a n-terminal de lisil-trna sintetase como princípio ativo para prevenção ou tratamento de doença relacionada com migração celular
BR112022010488A2 (pt) Formulação farmacêutica, uso da formulação farmacêutica, e, método para tratamento de um paciente
BR112018005494A2 (pt) composto, composição farmacêutica, e, método de tratamento de um paciente com uma doença.
BR112018008769A2 (pt) formulações farmacêuticas, formulações líquidas aquosa reconstituída e liofilizada, seringa, método de fabricação de uma formulação farmacêutica, método para tratamento de uma doença e uso de uma formulação reconstruída

Legal Events

Date Code Title Description
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]